GP5 and cancer: While prevalences for ATM, BRCA1, BRCA2, and PALB2 in this study are consistent with prevalences observed in the literature, we calculated that as many as 1.22% of individuals in both cohorts unselected for personal or family history of cancer harbored GPV in CHEK2.